Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

Figures & data

Table 1. Rating overall evidence’s credibility of the review.

Classes	Grading of evidences	Eligibility
I	Convincing evidence	Met all criteria
II	Highly suggestive evidence	Met 1 to 3 of the criteria
III	Suggestive evidence	Required only a P < 0.001 by random-effects and > 1000 participants
IV	Weak evidence	Required only a P < 0.05 under random-effects
V	No significant evidence	P ≥ 0.05under random-effects

Figure 1. Flowchart of the study selection process.

Figure 2. Pool GRADE of evidence of association of different factors and HepB.

^aProtect free from prevalence of anti-HBc (+++) and HBAsg (++); ^bBooster dose (+++), Booster in 10–20-year-old (++), Booster in 20–30-year-old (+); ^cSeroprotection in 28 wks (++), in 50 wks (+); ^dHepB: Hepatitis B virus vaccine; ^eGM-CSF: granulocyte macrophage colony-stimulating factor; ^hHBIG: Hepatitis B immunoglobulin; ⁱAnti-TNFs: Anti-tumor necrosis factors.

Figure 3. Forest plot of vaccination strategies and the efficacy of HepB.

Figure 4. Forest plot of vaccination strategies and the safety of HepB.

Figure 5. Forest plot of different characteristics and the efficacy of HepB.

*AIR: adequate immune response, AIR.